ARS Pharmaceuticals' Needle-Free Epinephrine Spray Gains Canadian Approval

Event summary

  • Health Canada approved neffy (epinephrine nasal spray) for emergency treatment of anaphylaxis in adults and children over 30 kg.
  • ARS Pharmaceuticals licensed neffy to ALK-Abello A/S for Canada, UK, and Europe, receiving $155 million in upfront and milestone payments.
  • ARS anticipates up to $310 million in additional regulatory and sales milestones, plus double-digit royalties on net sales.
  • neffy is expected to launch in Canada in summer 2026, with a pending filing for a 1 mg dose for children 15–30 kg.
  • China approved neffy in December 2025, with a pending filing for the 1 mg dose.

The big picture

ARS Pharmaceuticals' needle-free epinephrine spray, neffy, addresses critical limitations of traditional auto-injectors, including fear of needles and portability issues. The Canadian approval expands its footprint beyond the U.S., where it's already commercially available, and China, where it gained approval in late 2025. The licensing deal with ALK-Abello A/S underscores the strategic value of neffy in key global markets, with ARS standing to gain significant milestone payments and royalties as the product scales.

What we're watching

Market Adoption
Whether neffy can overcome existing auto-injector inertia and capture significant market share in Canada.
Regulatory Momentum
The pace at which ARS secures approvals for the 1 mg dose in both Canada and China.
Commercial Execution
How ALK-Abello A/S executes the commercial launch in Canada, given ARS's reliance on milestone payments.